Inhalon Biopharma is pioneering a novel inhaled antibody treatment platform designed to combat acute respiratory infections (ARIs) such as respiratory syncytial virus (RSV), human metapneumovirus (hMPV), influenza, and SARS-CoV-2. Their innovative approach utilizes "muco-trapping" antibodies, which are engineered to bind to pathogens in the mucus lining the airways. This mechanism not only prevents the spread of infections within the lungs but also facilitates the rapid clearance of these pathogens through the body's natural mucus clearance processes. The inhaled delivery method aims to enhance patient comfort and enable a "test-to-treat" model, allowing for effective treatment in a home setting.

Inhalon's technology is supported by a robust patent portfolio and has shown promising results in preclinical and clinical studies. Their inhaled antibodies have demonstrated significant efficacy in reducing viral loads in animal models, and early clinical trials indicate that these antibodies can achieve therapeutic levels in the respiratory tract. This platform is particularly advantageous as it requires lower doses compared to traditional systemic therapies, potentially leading to fewer side effects and improved patient outcomes. Inhalon's commitment to developing effective inhaled therapies positions them at the forefront of respiratory care innovation.

United States

Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications and sometimes death.

Inhalon Biopharma

Company Details